top of page

Cannabis-derived drug treating lung received $3M seed

RS BioTherapeutics received $3M capital from its second seed round to focus on developing a medication for chronic obstructive pulmonary disease, or COPD. Co-founder and Chief Strategy Officer Justin Molignoni said the company will apply for an investigational new drug application from the U.S. Food and Drug Administration and hopes to submit it in 2024.

bottom of page